Skip to main content

Table 3 Pretreatment HIV drug resistance among HIV-infected individuals initiating ART in 2017 in China, by region

From: Pretreatment HIV drug resistance in adults initiating antiretroviral therapy in China, 2017

 

Number

Number of PDR

Prevalence (%)

Prevalence (%)

NNRTIs

NRTIs

PIs

Total

1711

117

6.8

4.6(79/1711)

2.2 (38/1711)

0.6 (10/1711)

High prevalence regions

1102

90

8.2

5.5(61/1102)

2.8 (31/1102)

0.6 (7//1102)

Dehong, Yunnan

150

14

9.3

8.7(13/150)

0.7 (1/150)

0

Lincang, Yunnan

158

14

8.9

5.7(9/158)

3.8 (6/158)

1.3 (2/158)

Liuzhou, Guangxi

207

11

5.3

2.9(6/207)

1.9 (4/207)

0.5 (1/207)

Nanning, Guangxi

104

7

6.7

3.9(4/104)

3.8 (4/104)

0

Liangshan, Sichuan

279

34

12.2

9.0(25/279)

3.9 (11/279)

1.1 (3/279)

Neijiang, Sichuan

105

5

4.8

1.0(1/105)

2.9 (3/105)

1.0 (1/105)

Shenzhen, Guangdong

99

5

5.1

3.0(3/99)

2.0 (2/99)

0

Moderate prevalence regions

609

27

4.4

3.0(18/609)

1.1 (7/609)

0.5 (3/609)

Chongqing

85

5

5.9

2.4(2/85)

1.2 (1/85)

2.4 (2/85)

Guizhou

112

5

4.5

1.8(2/112)

1.8 (2/112)

0.9 (1/112)

Hunan

97

2

2.1

2.1(2/97)

1.0 (1/97)

0

Beijing

111

4

3.6

2.7(3/111)

0.9 (1/111)

0

Jiangsu

105

5

4.8

4.8(5/105)

0

0

Shandong

99

6

6.1

4.0(4/99)

2.0 (2/99)

0

  1. PDR Pretreatment drug resistance, NNRTI Non-nucleoside reverse transcriptase inhibitor, NRTI nucleoside reverse transcriptase inhibitor, PI Protease inhibitor.